• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·3164.TW
Share

GenMont Biotech Incorporation Stocks

NT$ 16.85Last Updated 20.10.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 44.56M

NT$ 16.85
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Taiwan, GenMont Biotech Incorporation is primarily engaged in the comprehensive process of developing, manufacturing, and marketing functional probiotic products. Beyond its core offerings, the company also provides specialized probiotic formulations. It extends its services to include original formula design and production for health-oriented food items, as well as supplying relevant manufacturing equipment. Additionally, GenMont Biotech actively collaborates on the research, production, and clinical evaluation of a variety of other products. The company was established in 2000 and has its headquarters situated in Tainan City, Taiwan.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 04:37

AI stocks surged: one of the largest server suppliers eased market concerns

21.10.2026 03:02

SpaceX and Tesla Are Discussing a Merger — Musk

21.10.2026 01:11

SpaceX's profit more than doubled expectations. The annual revenue target is $1 trillion.

21.10.2026 00:45

The Wells Fargo indicator has issued a buy signal for the first time in nearly 1.5 years

20.10.2026 23:27

AI giants are pushing for data center savings. Who stands to lose?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026